[go: up one dir, main page]

BRPI0817387A2 - métodos de conformidade de suplementação dietária de uridina e uso dos mesmos - Google Patents

métodos de conformidade de suplementação dietária de uridina e uso dos mesmos

Info

Publication number
BRPI0817387A2
BRPI0817387A2 BRPI0817387A BRPI0817387A BRPI0817387A2 BR PI0817387 A2 BRPI0817387 A2 BR PI0817387A2 BR PI0817387 A BRPI0817387 A BR PI0817387A BR PI0817387 A BRPI0817387 A BR PI0817387A BR PI0817387 A2 BRPI0817387 A2 BR PI0817387A2
Authority
BR
Brazil
Prior art keywords
uridine supplementation
dietary
compliance methods
compliance
methods
Prior art date
Application number
BRPI0817387A
Other languages
English (en)
Inventor
Richard Wurtman
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of BRPI0817387A2 publication Critical patent/BRPI0817387A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/46—NMR spectroscopy
    • G01R33/465—NMR spectroscopy applied to biological material, e.g. in vitro testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/483—NMR imaging systems with selection of signals or spectra from particular regions of the volume, e.g. in vivo spectroscopy
    • G01R33/485—NMR imaging systems with selection of signals or spectra from particular regions of the volume, e.g. in vivo spectroscopy based on chemical shift information [CSI] or spectroscopic imaging, e.g. to acquire the spatial distributions of metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0817387A 2007-11-02 2008-11-03 métodos de conformidade de suplementação dietária de uridina e uso dos mesmos BRPI0817387A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99614607P 2007-11-02 2007-11-02
PCT/US2008/082265 WO2009059306A1 (en) 2007-11-02 2008-11-03 Uridine dietary supplementation compliance methods and use thereof

Publications (1)

Publication Number Publication Date
BRPI0817387A2 true BRPI0817387A2 (pt) 2015-09-08

Family

ID=40588272

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817387A BRPI0817387A2 (pt) 2007-11-02 2008-11-03 métodos de conformidade de suplementação dietária de uridina e uso dos mesmos

Country Status (6)

Country Link
US (1) US8551452B2 (pt)
EP (1) EP2217075A4 (pt)
CN (2) CN101896119A (pt)
BR (1) BRPI0817387A2 (pt)
HK (1) HK1223685A1 (pt)
WO (1) WO2009059306A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012125020A1 (en) 2011-03-14 2012-09-20 N.V. Nutricia Method for treating neurotrauma
WO2015084158A1 (en) * 2013-12-06 2015-06-11 N.V. Nutricia A pyrimidine derivative and a fatty acid source for use in the treatment of constipation
WO2015115885A1 (en) * 2014-01-31 2015-08-06 N.V. Nutricia Method for reducing white matter lesions, white matter hyperintensities (wmh), leukoaraiosis or periventricular white matter disease in elderly
WO2017069613A1 (en) 2015-10-23 2017-04-27 N.V. Nutricia Method for improving recognition and/or working memory in hyperphenylalanimenia and phenylketonuria patients

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221784A (en) 1979-04-05 1980-09-09 Massachusetts Institute Of Technology Process and composition for treating disorders by administering lecithin
IT1178044B (it) 1984-10-09 1987-09-03 Polifarma Spa Agente attivo farmaceutico per il trattamento di patologie cerebrali a base di uridina
CA1321994C (en) 1987-10-28 1993-09-07 Reid Von Borstel Acylated uridine and cytidine and uses thereof
US5470838A (en) 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
IT1219667B (it) 1988-06-21 1990-05-24 Polifarma Spa Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
US5141943A (en) 1990-04-12 1992-08-25 Brown University Research Foundation 5-benzyl barbiturate derivatives
IT1241984B (it) 1990-06-13 1994-02-02 Polifarma Spa Impiego di uridina nel trattamento farmacologico delle complicazioni periferiche del diabete
US6294914B1 (en) * 1993-06-02 2001-09-25 The Board Of Trustees Of The University Of Illinois Method of enhancing an MRI signal
US20050027004A1 (en) 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
US5567689A (en) 1993-08-13 1996-10-22 The Uab Research Foundation Methods for increasing uridine levels with L-nucleosides
JPH07215879A (ja) 1994-02-02 1995-08-15 Otsuka Pharmaceut Factory Inc 抗ストレス組成物
DK0680762T3 (da) 1994-05-06 2002-09-30 Esp Farmaceuticas Centrum Sa Farmaceutisk sammensætning til brug i behandlingen af neurodegenerative dysfunktioner
JPH0930976A (ja) 1995-07-17 1997-02-04 Otsuka Pharmaceut Factory Inc 記憶低下改善剤
US5843024A (en) 1996-05-17 1998-12-01 Breonics, Inc. Solution and process for resuscitation and preparation of ischemically damaged tissue
US5962459A (en) 1996-05-28 1999-10-05 Polifarma S.P.A. Therapeutic active agent for treatment of neuron degenerative diseases
IT1290781B1 (it) 1996-05-28 1998-12-10 Polifarma Spa Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
US5958896A (en) 1997-08-08 1999-09-28 The Mclean Hospital Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure
US5977174A (en) 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6132724A (en) 1998-04-29 2000-10-17 City Of Hope National Medical Center Allelic polygene diagnosis of reward deficiency syndrome and treatment
US20060069061A1 (en) 1998-07-31 2006-03-30 Dick Wurtman Compositions containing uridine and choline, and methods utilizing same
ES2294850T3 (es) * 1998-07-31 2008-04-01 Massachusetts Institute Of Technology Tratamiento de la enfermedad de alzheimer mediante el aumento de los niveles de citidina in vivo.
US20050203053A1 (en) 1999-07-30 2005-09-15 Wurtman Richard J. Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
US8518882B2 (en) 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
NZ513926A (en) 1999-02-23 2001-09-28 Univ California Methods of treatment of mitochondrial disorders
JP2001233776A (ja) 2000-02-25 2001-08-28 Yamasa Shoyu Co Ltd 学習・記憶能低下改善剤およびその用途
US6819952B2 (en) * 2001-03-23 2004-11-16 The Board Of Trustees Of The Leland Stanford Junior University Magnetic resonance spectroscopic imaging method to monitor progression and treatment of neurodegenerative conditions
GB0111282D0 (en) 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
US20030114415A1 (en) 2001-12-14 2003-06-19 Wurtman Richard J. Compositions and methods for treating and preventing memory impairment using citicoline
JP2007508315A (ja) 2003-10-08 2007-04-05 ザ マクレーン ホスピタル コーポレーション ω−３脂肪酸を含む組み合わせを用いて、精神障害、物質乱用障害、および他の障害を治療する方法
WO2005122767A1 (en) * 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
KR100645184B1 (ko) * 2004-11-18 2006-11-10 주식회사 엘지화학 열가소성탄성체를 이용한 탈ｐｖｃ바닥재 및 그의 제조방법
ATE408205T1 (de) * 2005-04-01 2008-09-15 Koninkl Philips Electronics Nv Verfahren, system und computerprogramm zum segmentieren einer struktur in einem datensatz
AU2006251562B2 (en) * 2005-05-23 2012-03-22 Massachusetts Institute Of Technology Compositions containing PUFA and methods of use thereof
US9078628B2 (en) * 2005-05-25 2015-07-14 Koninklijke Philips N.V. Off-magnet patient scan positioning
ATE509624T1 (de) * 2005-12-23 2011-06-15 Nutricia Nv Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz

Also Published As

Publication number Publication date
US20090117051A1 (en) 2009-05-07
CN101896119A (zh) 2010-11-24
HK1223685A1 (zh) 2017-08-04
CN105510850A (zh) 2016-04-20
WO2009059306A1 (en) 2009-05-07
EP2217075A4 (en) 2012-01-25
EP2217075A1 (en) 2010-08-18
US8551452B2 (en) 2013-10-08

Similar Documents

Publication Publication Date Title
NO2022027I1 (no) Combination of daunorubicin and cytarabine
BRPI0909077A2 (pt) Artigos multicamadas e métodos de preparo e uso dos mesmos
PT2963031T (pt) Pró-fármacos de tetrahidrocanabinol, composições compreendendo pró-fármacos de tetrahidrocanabinol e métodos de utilização dos mesmos
BRPI0807495A2 (pt) Adjuvantes e métodos de emrpego dos mesmos
BRPI0920927A2 (pt) derivados de azaquinolinona e usos dos mesmos
BRPI1010024A2 (pt) derivados de aminopirrolidinona e uso dos mesmos
DE602007010981D1 (de) Cycloalkylaminsubstituierte isochinolin- und isochinolinonderivate
BRPI0815811A2 (pt) Derivados de indol substituído e métodos de uso dos mesmos
BRPI0819909A2 (pt) anticorpos antimesotelina e usos dos mesmos
CY2015013I1 (el) Αντι-μολυσματικες πυραμιδινες και χρησεις αυτων
BRPI0916769A2 (pt) derivados de benzilbenzeno deuterados e métodos de uso
EP2352816A4 (en) HUMAN TEMPORARY CELLS
BRPI0922807A2 (pt) imonuglobulinas de domínio variável duplo e usos dos mesmos
BRPI1014544A2 (pt) anticorpors anti-il-17f e metodos de uso dos mesmos
DK2081955T3 (da) Metastinderivater og anvendelse deraf
BRPI0816350A2 (pt) Composições orais, produtos e métodos de uso
BRPI0909954A2 (pt) "diazacarbazóis e métodos de uso"
DOP2010000044A (es) Derivado de oxopirazina y herbicida
EP1987068A4 (en) Modification of oligosaccharides and labeling of proteins
BRPI0812562A2 (pt) composições terapêuticas anti-cd20 e métodos
BRPI0809818A2 (pt) "composição de alimento seco e composição de alimento seco vegetariano"
BRPI0906980A2 (pt) Composição de derivados e maleatados
BRPI0812909A2 (pt) Derivados de guanina policíclica e métodos de uso dos mesmos.
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI0905715A2 (pt) Composição farmacêutica e kit de componentes

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: A01N 65/00

Ipc: A61K 49/10 (2006.01), G01R 33/465 (2006.01), G01R

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements